+63.9%
CSCO vs MRNA
+511.3%
-447.4%
-16.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | -2.2% | +2.8% | +0.5% |
| 7D | -0.7% | +5.5% | -6.1% | -0.7% |
| 30D | -10.1% | +158.7% | -168.9% | -10.4% |
| 3M | -15.7% | +182.1% | -197.8% | -17.2% |
| 6M | +36.3% | +151.8% | -115.5% | +34.5% |
| YTD | +43.8% | +393.6% | -349.7% | +36.5% |
| 1Y | +63.9% | +499.5% | -435.5% | +52.7% |
| All | +63.9% | +511.3% | -447.4% | +52.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling